Conflicting evidence on the frequency of ESR1 amplification in breast cancer

Nature Genetics (Impact Factor: 29.65). 08/2008; 40(7):821-2. DOI: 10.1038/ng0708-821
Source: PubMed

ABSTRACT An earlier report of high-frequency ESR1 amplification in breast cancer is now challenged by correspondence from four groups. This discussion of whether or not there is something 'FISHy' about ESR1 amplification highlights the difficulty of validating such observations, leaving the frequency and clinical significance of ESR1 amplification in breast cancer an open question.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer occurs at a high frequency in women and, given this fact, a primary focus of breast cancer research has been the study of estrogen receptor α (ER) signaling. However, androgens are known to play a role in normal breast physiology and therefore androgen receptor (AR) signaling is becoming increasingly recognized as an important contributor towards breast carcinogenesis. Moreover, the high frequency of AR expression in breast cancer makes it an attractive therapeutic target, but the ability to exploit AR for therapy has been difficult. Here we review the historical use of androgen/anti-androgen therapies in breast cancer, the challenges of accurately modeling nuclear hormone receptor signaling in vitro, and the presence and prognostic significance of AR in breast cancer.
    American Journal of Cancer Research 01/2012; 2(4):434-45. · 3.97 Impact Factor
  • New England Journal of Medicine 09/2008; 359(7):722-34. DOI:10.1056/NEJMra0803109 · 54.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are large-scale molecular differences between estrogen receptor (ER)-positive and ER-negative breast cancers. Endocrine therapy has become the most important treatment option for women with ER-positive breast cancer, and approximately 70% of primary breast cancers express ERalpha. Endocrine therapy has provided meaningful advances in breast cancer treatment and prevention. However, some patients continue to develop recurrence and die of the disease. New insights into ER biology and progress in the understanding of resistance mechanisms are generating tremendous promise for new therapeutic opportunities to target resistance and improve disease outcomes.
    International Journal of Clinical Oncology 11/2008; 13(5):380-3. DOI:10.1007/s10147-008-0818-7 · 2.17 Impact Factor